periplogenin 3-O-β-D-glucopyranosyl-(1->4)-O-β-D-digitoxopyranoside | 210637-17-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: periplogenin 3-O-β-D-glucopyranosyl-(1->4)-O-β-D-digitoxopyranoside
• 英文别名: periplogenin 3-O-β-D-glucopyranosyl (1→4)-O-β-D-digitoxopyranoside；periplogenin 3-O-β-D-glucopyranosyl-(1→4)-O-β-D-digitoxopyranoside；corchorusoside C；3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• CAS: 210637-17-5
• 化学式: C₃₅H₅₄O₁₃
• 分子量: 682.806
• InChiKey: ZOSJMTBTUZXPSR-MGSYXVBGSA-N

物化性质

• 沸点：
  877.4±65.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  48
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  205
• 氢给体数：
  7
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  periplogenin 3-O-β-D-glucopyranosyl-(1->4)-O-β-D-digitoxopyranoside 在 盐酸 、 甲醇 作用下， 生成 甲基-Alpha-D-吡喃葡糖苷 、 (2R,3S,4S)-6-Methoxy-2-methyl-tetrahydro-pyran-3,4-diol 、 杠柳苷元
  参考文献：
  名称：

  Corchorusosides A, B, C, D, and E, New Cardiotonic Oligoglycosides from the Seed of Corchorus olitorius L. (Moroheiya)

  摘要：

  The methanolic extract of the seeds of Corchorus olitorius L. (Moroheiya) was found to show inhibitory effect against Na+-K+-ATPase and positive inotropic activity in the guinea pig isolated atria. Through bioassay-guided separation from the methanolic extract, new cardenolide oligoglycosides called corchorusosides A, B, C, D, and E were isolated together with six known cardenolide oligoglycosides. The structures of new corchorusosides were determined on the basis of chemical and physicochemical evidence. All cardenolide oligoglycosides from the seeds showed potent inhibitory activity against Na+,K+-ATPase, which was equivalent to those of digitoxin and ouabain. The methanolic extract, glycoside fraction, and principal glycoside showed potent acute toxicity by intraperitoneal administration, whereas they showed little acute toxicity by oral administration. Furthermore, by means of HPLC quantitative analysis of the cardiotonic oligoglycosides, it was found that the glycosides mainly distributed in the seeds, while the edible parts such as fresh young leaves and stems contained only trace amount.

  DOI：

  10.3987/com-98-8146

文献信息

• Topical and oral formulations of cardiac glycosides for treating skin diseases
  申请人：Streeper Robert

  公开号：US20060205679A1

  公开（公告）日：2006-09-14

  The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

  本发明提供了一种方法、制备和使用多种含有至少一种毛地黄苷类药物成分的药物组合物，例如奥利安定、奥多罗苷A、内里福林、普罗斯西拉里丁A、甲基普罗斯西拉里丁A、地高辛、地高辛或至少一种毛地黄苷类与环糊精络合的药物。另一方面，本发明提供了一种有效的方法来治疗哺乳动物的疾病。另一方面，本发明提供了一种有效的方法来治疗人类或非人类动物的皮肤疾病。
• MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN
  申请人：Hoffmann Erika

  公开号：US20100063585A1

  公开（公告）日：2010-03-11

  The invention relates to stents and catheter balloons having optimized coatings for eluting rapamycin as well as methods for manufacturing these coatings.

  本发明涉及具有优化涂层以释放雷帕霉素的支架和导管球囊，以及制造这些涂层的方法。
• MANUFACTURE, METHOD AND USE OF DRUG-ELUTING MEDICAL DEVICES FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN
  申请人：Hoffmann Erika

  公开号：US20130005758A1

  公开（公告）日：2013-01-03

  The invention relates to stents and catheter balloons having optimized coatings for eluting rapamycin as well as methods for manufacturing these coatings.

  本发明涉及具有经过优化的涂层以释放雷帕霉素的支架和导管球囊，以及制造这些涂层的方法。
• BALLOON CATHETER WITH POLYMERIC BALLOON HAVING A SURFACE MODIFIED BY A PHOTOACTIVATION REACTION AND METHOD OF MAKING
  申请人：D'Onofrio Simone

  公开号：US20140378897A1

  公开（公告）日：2014-12-25

  A balloon catheter, in particular a balloon catheter for angioplasty, the balloon having an inner or outer surface modified by means of a photoactivation reaction.

  一个气球导管，特别是用于血管成形术的气球导管，该气球通过光活化反应改性内部或外部表面。
• Expandable medical device for the treatment and prevention of cardiovascular diseases
  申请人：Perelson, Ophir

  公开号：EP1913962A1

  公开（公告）日：2008-04-23

  The invention relates to expandable medical devices such as stents, bioresorbable stents or catheter balloons with or without crimped stents comprising the pharmaceutically active agent gemcitabine as pure compound or incorporated into a drug release matrix optionally in combination with other drugs for the treatment of cardiovascular diseases such as arteriosclerosis, atherosclerosis, stenosis or restenosis and methods for the manufacture of these expandable medical devices.

  本发明涉及用于治疗动脉硬化、动脉粥样硬化、血管狭窄或再狭窄等心血管疾病的可膨胀医疗器械，如支架、生物可吸收支架或带或不带卷边支架的导管球囊，其中包含纯化合物形式的药物活性剂吉西他滨，或将其掺入药物释放基质（可选择与其他药物组合使用），以及制造这些可膨胀医疗器械的方法。